EUVIMEDEUVIMED entdecken
VergleichsstudieNetzwerk-MetaanalyseSystematische Übersicht

Comparative Efficacy of Colchicine and Intensive Low-density Lipoprotein Cholesterol Lowering in Patients with Atherosclerotic Diseases receiving Statins: A Network Meta-analysis of Randomized Controlled Trials

Zhenhong Ou, Fangchao Wang, Yunlin Chen, Xueyuan Liu, Boli Ran, Yuehui Yin, Kun Cui iD

Cardiovascular Drugs and Therapy · 2025-08 · 39 (4) · 811-822

DOI: 10.1007/s10557-024-07622-9 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 29.08.2024. Verfasst von Zhenhong Ou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Chongqing General Hospital of Chongqing University, Chongqing, China. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Atherosclerosis, Cholesterol, LDL, Colchicine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Adding intensive low-density lipoprotein cholesterol (LDL-C)-lowering agents or colchicine to statin has been shown to result in additional cardiovascular benefits for patients with atherosclerotic cardiovascular diseases (ASCVD). We aimed to compare the efficacy and safety of these supplementary agents in patients with ASCVD receiving statin. METHODS: We performed a systematic review and frequentist network meta-analysis of randomized controlled trials. The primary efficacy endpoint was the main adverse cardiovascular event (MACE), and the secondary efficacy endpoints were myocardial infarct, stroke, coronary revascularization, cardiovascular death, and all-cause mortality, respectively. The safety endpoints were treatment discontinuation and non-cardiovascular death. We obtained estimates for efficacy outcomes and safety endpoints and presented these estimates as risk ratio (RR) with 95% confidence intervals. We ranked the comparative efficacy and safety of all drugs with P-scores. RESULTS: Seventeen trials totaling 85,823 participants treated with colchicine (5926 participants), intensive LDL-C lowering (37,854 participants) via proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, Niemann-Pick C1-like 1 protein (NPC1L1) inhibitor or ATP citrate lyase (ACL) inhibitor, or statin alone (42,043 participants) were included. Colchicine was associated with a greater reduction in the risk of MACE (RR 0.72, 0.69-0.91), stroke (RR 0.55, 0.33-0.92), and coronary revascularization (RR 0.73, 0.60-0.90) compared with NPC1L1 inhibitor, and it provided a larger reduction in the risk of MACE (RR 0.79, 0.69-0.91) compared to PCSK9 inhibitor. However, colchicine was associated with increased risk of non-cardiovascular death compared with NPC1L1 inhibitor (RR 1.48, 1.04-2.10) and PCSK9 inhibitor (RR 1.57, 1.08-2.27). Although no regimen prolonged survival, colchicine had worse performance on non-cardiovascular death and all-cause mortality. CONCLUSIONS: In patients with ASCVD receiving statin, colchicine seems to be more effective than intensive LDL-C-lowering therapy with PCSK9 inhibitor or NPC1L1 inhibitor for cardiovascular prevention. However, using colchicine as an alternative to intensive LDL-C-lowering therapy may need to be weighed against the cardiovascular benefits and the potential harms of higher non-cardiovascular death. TRIAL REGISTRATION: PROSPERO Identifier: CRD42023441385.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anticholesteremic AgentsAtherosclerosisCholesterol, LDLColchicineDyslipidemiasHydroxymethylglutaryl-CoA Reductase InhibitorsHumansBiomarkersDrug Therapy, CombinationPCSK9 InhibitorsRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

ASCVDAnti-inflammatoryLow-density lipoprotein cholesterol loweringSecondary prevention

Substanzen

Anticholesteremic AgentsBiomarkersCholesterol, LDLColchicineHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology, Chongqing General Hospital of Chongqing University, Chongqing, China.
  • Department of Cardiology, Chongqing General Hospital, No. 118 Xingguang Avenue, Liangjiang New Area, Chongqing, 401120, China.
  • Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Cardiology, Graduate School of Medicine, Keio University, Tokyo, Japan.
  • Department of Cardiology, Chongqing General Hospital of Chongqing University, Chongqing, China. doccuikun1108@163.com.
  • Department of Cardiology, Chongqing General Hospital, No. 118 Xingguang Avenue, Liangjiang New Area, Chongqing, 401120, China. doccuikun1108@163.com.

ORCID-Profile: Kun Cui

Zitieren

APA

Ou, Z., Wang, F., Chen, Y., Liu, X., Ran, B., Yin, Y., & Cui, K. (2025). Comparative Efficacy of Colchicine and Intensive Low-density Lipoprotein Cholesterol Lowering in Patients with Atherosclerotic Diseases receiving Statins: A Network Meta-analysis of Randomized Controlled Trials. Cardiovascular Drugs and Therapy, 39(4), 811-822. https://doi.org/10.1007/s10557-024-07622-9

Vancouver

Ou Z, Wang F, Chen Y, Liu X, Ran B, Yin Y, et al. Comparative Efficacy of Colchicine and Intensive Low-density Lipoprotein Cholesterol Lowering in Patients with Atherosclerotic Diseases receiving Statins: A Network Meta-analysis of Randomized Controlled Trials. Cardiovascular Drugs and Therapy. 2025;39(4):811-822. doi:10.1007/s10557-024-07622-9

BibTeX
@article{Ou2025,
  author = {Ou, Zhenhong and Wang, Fangchao and Chen, Yunlin and Liu, Xueyuan and Ran, Boli and Yin, Yuehui and Cui, Kun},
  title = {Comparative Efficacy of Colchicine and Intensive Low-density Lipoprotein Cholesterol Lowering in Patients with Atherosclerotic Diseases receiving Statins: A Network Meta-analysis of Randomized Controlled Trials},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2025},
  volume = {39},
  number = {4},
  pages = {811--822},
  doi = {10.1007/s10557-024-07622-9}
}
Kostenlos starten →